Market Research Report
Organ-On-A-Chip Innovations Fueling Drug Screening Applications
|Published by||Frost & Sullivan||Product code||662141|
|Published||Content info||70 Pages
Delivery time: 1-2 business days
|Organ-On-A-Chip Innovations Fueling Drug Screening Applications|
|Published: June 29, 2018||Content info: 70 Pages||
Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry
Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication.
Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems.
US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.